News | June 23, 2015

First Patients Treated on Elekta Linear Accelerator with Integrated Brainlab ExacTrac X-Ray

Munich hospital using combined system for precision treatment of wide range of cancers

Brainlab, Exactrac, Elekta, Versa HD, LMU Medical Center, Munich

June 23, 2015 - Brainlab announced first patient treatments in March on a fully integrated radiation oncology solution that combines its ExacTrac patient positioning with the Elekta Versa HD linear accelerator (LINAC). Working in synergy, these technologies determine positioning and treatment accuracy for cancer patients.  

By streamlining treatment workflow, ExacTrac and Versa HD increase patient positioning efficiency and provide highly accurate solutions for frameless stereotactic radiosurgery (SRS) and stereotactic body radiotherapy treatment (SBRT). The accuracy is further enriched with the ability to detect and manage intra-fractional patient motion during treatment delivery.

The integrated ExacTrac/Versa HD solution is currently in routine clinical use at Ludwig-Maximilian University Hospital in Munich. To date, the hospital has treated 12 patients with a range of indications and has plans to expand their ExacTrac/Versa HD program.

"The LMU Medical Center prides itself on offering advanced technology and finding new ways to optimize our existing infrastructure. Combining these innovative cancer treatment technologies – Brainlab ExacTrac and Elekta Versa HD – allows us to maximize the benefits of both systems for our patients, including intra-fractional verification," said Prof. Claus Belka, medical director of radiotherapy and radiation oncology at LMU Medical Center, Grosshadern and Innenstadt clinics and polyclinics. "The integrated solution allows us to perform SRS and SBRT cases with submillimetric accuracy and the seamless workflow has allowed us to provide comfortable and fast treatment for patients."

The combined systems enable treatment of conventional as well as complex cancers that require highly accurate targeting precision, expanding the reach and richness of SRS and SBRT for facilities looking to leverage resources and deliver advanced, sophisticated therapies across several different LINACs.

For more information: www.brainlab.com

Related Content

Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more